FDA Approval of Dynavax's (DVAX) Groundbreaking Hep-B Vacccine Could Double Its Value - Cramer
Go back to FDA Approval of Dynavax's (DVAX) Groundbreaking Hep-B Vacccine Could Double Its Value - Cramer| Dynavax Technologies Corporation (NASDAQ: DVAX) | Delayed: 15.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.50 | 52 Week High | $29.86 | |||
| Open | $15.50 | 52 Week Low | $3.20 | |||
| Day High | $15.50 | P/E | N/A | |||
| Day Low | $15.50 | EPS | $-0.41 | |||
| Volume | 39,747 | |||||
